We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Kamada (KMDA) to Report Q1 Earnings: What's in the Cards?
Read MoreHide Full Article
Kamada Ltd. is scheduled to report first-quarter 2019 results on May 14.
The company has surpassed expectations in two of the trailing four quarters and missed in one, the average negative earnings surprise being 23.61%. It delivered a positive earnings surprise of a whopping 200% in the last reported quarter.
Kamada’s share price has increased 14.8% year to date compared with the industry’s growth of 2.7%.
Let's see how things are shaping up for this announcement.
Factors to Consider
Kamada’s revenues in 2018 were primarily driven by the successful launch and strong sales of KedRAB in the United States, the anti-rabies IgG product. The product is expected to drive sales in the first quarter of 2019 as well.
Last month, Kamada announced that the FDA has acknowledged the path forward for commencing a phase III study on the inhaled Alpha-1 Antitrypsin (Inhaled AAT) product, which is being developed for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). The latest letter stated that the inhaled AAT product has satisfactorily addressed all the grey areas previously conveyed by the agency.
In 2016, the company’s phase II study on the inhaled AAT product for treating AATD in the United States met the primary endpoint. However, the FDA expressed concerns about data from the European phase II/III study on the candidate, which was presented in April 2016.
Following this acknowledgement from the FDA, Kamada plans to start a pivotal phase III study in the second half of 2019. However, the timing of the program will depend on the successful completion of a human factor study (HFS), which is scheduled to begin soon. The HFS evaluation will assess the combination of the company’s inhaled AAT and PARI Pharma GmbH's eFlow nebulizer device.
Subsequently, Kamada expects to file an investigational new drug (IND) application in the United States and a Clinical Trial Authorization (CTA) in Europe to initiate the pivotal phase III study on the inhaled AAT product for registration thereafter. If successful, the company plans to use the outcomes from this study to resubmit an MAA in the EU and file a biologics license application (BLA) to the FDA. An update is expected on the call.
Further, in the proof-of-concept study on the IV-AAT program for the treatment of acute Graft versus Host Disease (GvHD), the company expects the completion of enrollment followed by the availability of interim data from this study by the end of 2019.
We expect Kamadato provide updates on all the aforementioned developments during the first-quarter earnings call.The company should also provide updates on the phase II study of IV-AAT for the prevention of lung transplant rejection, which is being conducted in collaboration with Shire, now part of Takeda (TAK - Free Report) .
What Our Model Indicates
Our proven model does not conclusively show that Kamada is likely to beat on earnings in the to-be-reported quarter. This is because the stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. But that is not the case here, as you will see below.
Earnings ESP: Kamada has an Earnings ESP of 0.00% as both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at a profit of 5 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company carries a Zacks Rank #3, which increases the predictive power of ESP. However, we need to have a positive Earnings ESP to be confident of an earnings beat.
Note that Sell-rated stocks (Zacks Rank #4 or 5) going into an earnings announcement are best avoided.
Here are some stocks you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
LogicBio Therapeutics, Inc. has an Earnings ESP of +25.84% and a Zacks Rank #3.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
Image: Bigstock
Kamada (KMDA) to Report Q1 Earnings: What's in the Cards?
Kamada Ltd. is scheduled to report first-quarter 2019 results on May 14.
The company has surpassed expectations in two of the trailing four quarters and missed in one, the average negative earnings surprise being 23.61%. It delivered a positive earnings surprise of a whopping 200% in the last reported quarter.
Kamada’s share price has increased 14.8% year to date compared with the industry’s growth of 2.7%.
Let's see how things are shaping up for this announcement.
Factors to Consider
Kamada’s revenues in 2018 were primarily driven by the successful launch and strong sales of KedRAB in the United States, the anti-rabies IgG product. The product is expected to drive sales in the first quarter of 2019 as well.
Last month, Kamada announced that the FDA has acknowledged the path forward for commencing a phase III study on the inhaled Alpha-1 Antitrypsin (Inhaled AAT) product, which is being developed for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). The latest letter stated that the inhaled AAT product has satisfactorily addressed all the grey areas previously conveyed by the agency.
In 2016, the company’s phase II study on the inhaled AAT product for treating AATD in the United States met the primary endpoint. However, the FDA expressed concerns about data from the European phase II/III study on the candidate, which was presented in April 2016.
Following this acknowledgement from the FDA, Kamada plans to start a pivotal phase III study in the second half of 2019. However, the timing of the program will depend on the successful completion of a human factor study (HFS), which is scheduled to begin soon. The HFS evaluation will assess the combination of the company’s inhaled AAT and PARI Pharma GmbH's eFlow nebulizer device.
Subsequently, Kamada expects to file an investigational new drug (IND) application in the United States and a Clinical Trial Authorization (CTA) in Europe to initiate the pivotal phase III study on the inhaled AAT product for registration thereafter. If successful, the company plans to use the outcomes from this study to resubmit an MAA in the EU and file a biologics license application (BLA) to the FDA. An update is expected on the call.
Further, in the proof-of-concept study on the IV-AAT program for the treatment of acute Graft versus Host Disease (GvHD), the company expects the completion of enrollment followed by the availability of interim data from this study by the end of 2019.
We expect Kamadato provide updates on all the aforementioned developments during the first-quarter earnings call.The company should also provide updates on the phase II study of IV-AAT for the prevention of lung transplant rejection, which is being conducted in collaboration with Shire, now part of Takeda (TAK - Free Report) .
What Our Model Indicates
Our proven model does not conclusively show that Kamada is likely to beat on earnings in the to-be-reported quarter. This is because the stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. But that is not the case here, as you will see below.
Earnings ESP: Kamada has an Earnings ESP of 0.00% as both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at a profit of 5 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company carries a Zacks Rank #3, which increases the predictive power of ESP. However, we need to have a positive Earnings ESP to be confident of an earnings beat.
Note that Sell-rated stocks (Zacks Rank #4 or 5) going into an earnings announcement are best avoided.
Kamada Ltd. Price and EPS Surprise
Kamada Ltd. price-eps-surprise | Kamada Ltd. Quote
Stocks That Warrant a Look
Here are some stocks you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
CannTrust Holdings Inc. is scheduled to release results on May 14. The company has an Earnings ESP of +6.25% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
LogicBio Therapeutics, Inc. has an Earnings ESP of +25.84% and a Zacks Rank #3.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
See Latest Stocks Today >>